Health and Healthcare
Dendreon Shares Losing House Committee Hope (DNDN)
Published:
Last Updated:
CNBC’s Mike Huckman just announced what is going to be a disappointment for Dendreon (NASDAQ: DNDN) holders, and that may be an understatement. The House Committee will not be forcing any action or pressing the FDA over Dendreon’s PROVENGE until FDA makes a final decision, and that could be one to three years away. There had been hopes that the committee would uncover conflicts of interest that have been alleged by many hopeful patients and investors alike. That doesn’t look to be in the realm of possibilities now.
As a reminder, there is still hope that the EU might actually save it when the FDA wouldn’t.
Dendreon shares are now down over 7% to $5.37, and its 52-week trading range is $3.57 to $25.25.
Jon C. Ogg
February 13, 2008
Travel Cards Are Getting Too Good To Ignore
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
